- Home
- HRTX vs IVA Comparison
HRTX vs IVA Comparison
Compare HRTX & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- IVA
- Stock Information
- Founded
- HRTX 1983
- IVA 2011
- Country
- HRTX United States
- IVA France
- Employees
- HRTX N/A
- IVA N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- IVA Health Care
- Exchange
- HRTX Nasdaq
- IVA Nasdaq
- Market Cap
- HRTX 325.0M
- IVA 359.6M
- IPO Year
- HRTX 1987
- IVA 2020
- Fundamental
- Price
- HRTX $1.98
- IVA $3.29
- Analyst Decision
- HRTX Strong Buy
- IVA Strong Buy
- Analyst Count
- HRTX 2
- IVA 4
- Target Price
- HRTX $5.00
- IVA $10.50
- AVG Volume (30 Days)
- HRTX 1.1M
- IVA 27.3K
- Earning Date
- HRTX 08-05-2025
- IVA 03-26-2025
- Dividend Yield
- HRTX N/A
- IVA N/A
- EPS Growth
- HRTX N/A
- IVA N/A
- EPS
- HRTX N/A
- IVA N/A
- Revenue
- HRTX $148,518,000.00
- IVA $14,591,573.00
- Revenue This Year
- HRTX $12.08
- IVA $15.38
- Revenue Next Year
- HRTX $12.57
- IVA $24.22
- P/E Ratio
- HRTX N/A
- IVA N/A
- Revenue Growth
- HRTX 12.43
- IVA N/A
- 52 Week Low
- HRTX $1.04
- IVA $1.53
- 52 Week High
- HRTX $3.73
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- HRTX 49.25
- IVA 45.22
- Support Level
- HRTX $1.90
- IVA $3.25
- Resistance Level
- HRTX $2.07
- IVA $3.57
- Average True Range (ATR)
- HRTX 0.10
- IVA 0.27
- MACD
- HRTX 0.00
- IVA -0.02
- Stochastic Oscillator
- HRTX 32.81
- IVA 22.64
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.